Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 177Head & Neck 27Gastrointestinal 27Breast 24CNS 21Genitourinary 18Sarcoma 11Other solid neoplasm 8Tumor-Agnostic 6Gynecologic 6Endocrine 4Dermatologic 3Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 1371Cyclophosphamide 1297Vincristine 662Doxorubicin 583Etoposide 525Prednisone 505Cytarabine 481fludarabine 462Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gefitinib × Lymphoid × Clear all
NCT01602289 2015-06-08

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
17 enrolled
LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡